Swiss Biotech report: More revenues, fewer companies


Zurich – The Swiss biotech industry has grown in 2006 in terms of revenues and profits. However, the number of companies decreased. These are the conclusions of this year’s Swiss Biotech Report, carried out by Ernst & Young (E&Y).
By the end of 2006, the Swiss sector consisted of 218 so called ELISCOs (Entrepreneurial LIfe Sciences COmpanies) – five percent less than in 2005 (229). E&Y defines “ELISCOs” as firms, which “use modern biological techniques to develop products or services”. Pharma or Agribiotech businesses, with only secondary activities in biotech, are excluded, as well as Swiss subsidiaries of foreign biotech companies.
At the end of 2006, more than 14.300 people were employed in the Swiss biotech sector, 6.867 of them work for “ELISCOs”. This number marks a 3% increase compared to 2006. However, public Swiss biotech companies employed 3% less people than in 2006. This number includes the staff of Serono, which was bought by the German Merck KGaA. The acquisition only became effective in early 2007. In terms of financing, Switzerland has had a very successful year with a140 million of venture capital flowing mostly into small and medium-sized firms. This value marks the highest amount invested since the burst of the bubble at the turn of the milennium.
Regarding company size, the Swiss biotech industry can be split into three main categories: the nine public companies, including globally active and well-known biotech leaders such as Actelion, and about 20 medium-sized firms with 50 to 100 employees. Some of these companies are now ready for an IPO or another capital market transaction.

Red biotech dominant

Historically, the Swiss industry has been a strong player in the pharmaceutical and chemical fields. Consequently, 85% of the 137 Swiss biotech developers are active in the field of red biotech, while only 7% are focusing on white biotech and 8% on green biotech. Geographically, the majority of Swiss biotech companies are located in the areas around Geneva, Basel and Zurich.



Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...



London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...



Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...



After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...



The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...



Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...



Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....



Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2016 BIOCOM



Current issue

All issues

Product of the week


Stock list

All quotes


  • ZEALAND PHARMA (DK)131.00 DKK10.08%
  • DIAMYD MEDICAL -B- (S)4.69 SEK8.56%
  • IPSEN (F)59.44 EUR6.68%


  • MOLOGEN (D)2.05 EUR-10.87%
  • PHARMING (NL)0.22 EUR-8.33%
  • VALNEVA (F)2.40 EUR-4.38%


  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)55.41 USD50.8%
  • VERNALIS (UK)44.50 GBP35.9%


  • MOLOGEN (D)2.05 EUR-30.5%
  • SANTHERA (CH)55.00 CHF-26.8%
  • NICOX (F)10.49 EUR-14.3%


  • KARO BIO (S)31.20 SEK1874.7%
  • NICOX (F)10.49 EUR455.0%
  • SAREUM HOLDINGS (UK)0.77 GBP234.8%


  • BB BIOTECH (D)44.84 EUR-84.7%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 28.07.2016


All Events